THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $147 | -63.6% | 17,264 | -61.6% | 0.00% | – |
Q1 2024 | $404 | -56.3% | 45,011 | -45.3% | 0.00% | – |
Q4 2023 | $925 | +360.2% | 82,357 | +253.9% | 0.00% | – |
Q3 2023 | $201 | -32.6% | 23,269 | -19.3% | 0.00% | – |
Q2 2023 | $298 | -24.9% | 28,823 | -21.3% | 0.00% | – |
Q1 2023 | $397 | +49.8% | 36,602 | +54.9% | 0.00% | – |
Q4 2022 | $265 | -99.8% | 23,623 | +111.0% | 0.00% | – |
Q3 2022 | $114,000 | -40.0% | 11,198 | -46.6% | 0.00% | – |
Q2 2022 | $190,000 | -30.7% | 20,967 | -26.8% | 0.00% | – |
Q1 2022 | $274,000 | -86.9% | 28,624 | -84.8% | 0.00% | – |
Q4 2021 | $2,088,000 | +380.0% | 188,818 | +221.2% | 0.00% | – |
Q3 2021 | $435,000 | +335.0% | 58,790 | +756.0% | 0.00% | – |
Q2 2021 | $100,000 | -90.4% | 6,868 | -86.6% | 0.00% | -100.0% |
Q1 2021 | $1,047,000 | +125.6% | 51,320 | +96.6% | 0.00% | – |
Q4 2020 | $464,000 | -27.2% | 26,104 | -39.5% | 0.00% | – |
Q3 2020 | $637,000 | -57.4% | 43,120 | -39.5% | 0.00% | -100.0% |
Q2 2020 | $1,495,000 | +48.8% | 71,244 | +63.7% | 0.00% | 0.0% |
Q1 2020 | $1,005,000 | -29.0% | 43,523 | -20.4% | 0.00% | 0.0% |
Q4 2019 | $1,416,000 | +61.1% | 54,708 | +21.4% | 0.00% | 0.0% |
Q3 2019 | $879,000 | -51.2% | 45,080 | -59.1% | 0.00% | 0.0% |
Q2 2019 | $1,800,000 | +80.0% | 110,239 | +150.0% | 0.00% | 0.0% |
Q1 2019 | $1,000,000 | +107.9% | 44,093 | +135.1% | 0.00% | – |
Q4 2018 | $481,000 | -53.3% | 18,752 | -40.4% | 0.00% | -100.0% |
Q3 2018 | $1,029,000 | -53.8% | 31,486 | -67.9% | 0.00% | -50.0% |
Q2 2018 | $2,227,000 | -14.0% | 98,139 | -8.1% | 0.00% | 0.0% |
Q1 2018 | $2,590,000 | +944.4% | 106,825 | +1101.4% | 0.00% | – |
Q4 2017 | $248,000 | +213.9% | 8,892 | +281.6% | 0.00% | – |
Q3 2017 | $79,000 | +11.3% | 2,330 | +31.9% | 0.00% | – |
Q2 2017 | $71,000 | -88.3% | 1,767 | -89.3% | 0.00% | -100.0% |
Q1 2017 | $607,000 | +427.8% | 16,475 | +355.4% | 0.00% | – |
Q4 2016 | $115,000 | +62.0% | 3,618 | +87.9% | 0.00% | – |
Q3 2016 | $71,000 | -76.7% | 1,926 | -85.7% | 0.00% | – |
Q2 2016 | $305,000 | +4257.1% | 13,489 | +3421.9% | 0.00% | – |
Q1 2016 | $7,000 | -93.8% | 383 | -94.6% | 0.00% | – |
Q4 2015 | $113,000 | +25.6% | 7,050 | -22.2% | 0.00% | – |
Q3 2015 | $90,000 | +1185.7% | 9,057 | +1486.2% | 0.00% | – |
Q2 2015 | $7,000 | -63.2% | 571 | -49.8% | 0.00% | – |
Q1 2015 | $19,000 | -75.0% | 1,138 | -78.5% | 0.00% | – |
Q4 2014 | $76,000 | -30.3% | 5,304 | +13.0% | 0.00% | – |
Q3 2014 | $109,000 | -61.8% | 4,692 | -48.7% | 0.00% | – |
Q2 2014 | $285,000 | – | 9,145 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |